Abstract
The typical way of judging about either the efficacy of a new treatment or, on the contrary, the damage of a pollutant agent is through a test of hypothesis having its ineffectiveness as null hypothesis. This is the typical operational field of Kolmogorov’s statistical framework where wastes of data (for instance non significant deaths in a polluted region) represent the main drawback. Instead, confidence intervals about treatment/pollution effectiveness are a way of exploiting all data, whatever their number is. We recently proposed a new statistical framework, called Algorithmic Inference, for overcoming crucial difficulties usually met when computing these intervals and abandoning general simplifying hypotheses such as errors’ Gaussian distribution. When effectiveness is expressed in terms of regression curves between observed data we come to a learning problem that we solve by identifying a region where the whole curve lies with a given confidence. The approach to inference we propose is very suitable for identifying these regions with great accuracy, even in the case of nonlinear regression models and/or a limited size of the observed sample, provided that a normally powered computing station is available. In the paper we discuss this new way of extracting functions from the experimental data and drawing conclusions about the treatments originating them. From an operational perspective, we give the general layout of the procedure for computing confidence regions as well as some applications on real data.
Keywords: confidence intervals, confidence regions, algorithmic inference, twisting argument, learning functions, linear regression, nonlinear regression
Current Pharmaceutical Design
Title: Appreciation of Medical Treatments Through Confidence Intervals
Volume: 13 Issue: 15
Author(s): B. Apolloni, S. Bassis, S. Gaito and D. Malchiodi
Affiliation:
Keywords: confidence intervals, confidence regions, algorithmic inference, twisting argument, learning functions, linear regression, nonlinear regression
Abstract: The typical way of judging about either the efficacy of a new treatment or, on the contrary, the damage of a pollutant agent is through a test of hypothesis having its ineffectiveness as null hypothesis. This is the typical operational field of Kolmogorov’s statistical framework where wastes of data (for instance non significant deaths in a polluted region) represent the main drawback. Instead, confidence intervals about treatment/pollution effectiveness are a way of exploiting all data, whatever their number is. We recently proposed a new statistical framework, called Algorithmic Inference, for overcoming crucial difficulties usually met when computing these intervals and abandoning general simplifying hypotheses such as errors’ Gaussian distribution. When effectiveness is expressed in terms of regression curves between observed data we come to a learning problem that we solve by identifying a region where the whole curve lies with a given confidence. The approach to inference we propose is very suitable for identifying these regions with great accuracy, even in the case of nonlinear regression models and/or a limited size of the observed sample, provided that a normally powered computing station is available. In the paper we discuss this new way of extracting functions from the experimental data and drawing conclusions about the treatments originating them. From an operational perspective, we give the general layout of the procedure for computing confidence regions as well as some applications on real data.
Export Options
About this article
Cite this article as:
Apolloni B., Bassis S., Gaito S. and Malchiodi D., Appreciation of Medical Treatments Through Confidence Intervals, Current Pharmaceutical Design 2007; 13 (15) . https://dx.doi.org/10.2174/138161207780765891
DOI https://dx.doi.org/10.2174/138161207780765891 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptides and their Metal Complexes in Neurodegenerative Diseases: from Structural Studies to Nanomedicine Prospects
Current Medicinal Chemistry Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases
CNS & Neurological Disorders - Drug Targets Effects of Proteoglycans on Oxidative/Nitrative Stress
Current Organic Chemistry Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy The Role of β-Amyloid Protein in Synaptic Function: Implications for Alzheimers Disease Therapy
Current Neuropharmacology A Simple High Efficiency Intra-Islet Transduction Protocol Using Lentiviral Vectors
Current Gene Therapy Reactive Astrogliosis: Role in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Putative Breast Tumor Suppressor TACC2 Suppresses the Aggressiveness of Breast Cancer Cells through a PLCγ Pathway
Current Signal Transduction Therapy Cilostazol: Therapeutic Potential Against Focal Cerebral Ischemic Damage
Current Pharmaceutical Design Brain-targeted Nano-architectures for Efficient Drug Delivery and Sensitization in Glioblastoma
Current Pharmaceutical Design Editorial [Hot Topic: Why Apoptosis in Pediatric Disorders?]
Current Pediatric Reviews Steroids and Vasopressor-Resistant Hypotension in Preterm Infants
Current Pediatric Reviews Targeting the Alpha 7 Nicotinic Acetylcholine Receptor to Reduce Amyloid Accumulation in Alzheimers Disease Pyramidal Neurons
Current Pharmaceutical Design Memantine: A Therapeutic Approach in Treating Alzheimers and Vascular Dementia
Current Drug Targets - CNS & Neurological Disorders Neuroprotective Role of Nanoparticles Against Alzheimer's Disease
Current Drug Metabolism Nucleic Acid Aptamers as Novel Class of Therapeutics to Mitigate Alzheimer’s Disease Pathology
Current Alzheimer Research Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology Caspases: Structure-Guided Design of Drugs to Control Cell Death
Mini-Reviews in Medicinal Chemistry The Endocannabinoid System and Schizophrenia: Integration of Evidence
Current Pharmaceutical Design Resveratrol Protects β Amyloid-Induced Oxidative Damage and Memory Associated Proteins in H19-7 Hippocampal Neuronal Cells
Current Alzheimer Research